Program
RSV+HMPV vaccine
Also written as “Investigational RSV+hMPV vaccine”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.
Furthest: phase 2, since Nov 11, 20242 company-led studies, 2 open or runningNext primary completion: Jan 18, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 22 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | Jan 18, 2027phase 2 · NCT06686654 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2024First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT06686654 · 1,530 enrolled · United States
- Jul 21, 2026Phase 2 study in Respiratory Syncytial Virus ImmunizationNCT07734649 · 2,400 planned · United States
Ahead
- Jan 18, 2027Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT06686654
- May 3, 2028Primary completion: phase 2 study in Respiratory Syncytial Virus ImmunizationNCT07734649
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RSV+HMPV vaccine”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07734649Respiratory Syncytial Virus Immunization · United States | 2 | Recruiting | May 3, 2028 | 2,400 |
| NCT06686654Respiratory Syncytial Virus Infections · United States | 2 | Active, not recruiting | Jan 18, 2027 | 1,530 |
How it is read
Names in the registry
- “RSV+HMPV vaccine”, 1 entry
- “Investigational RSV+hMPV vaccine”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.